Replicate designs [RSABE / ABEL]

posted by rajasekhar – India, 2017-01-07 08:04 (2956 d 12:38 ago) – Posting: # 16938
Views: 3,995

I am looking for a reference to on what basis we are doing partially and fully replicate studies for high variable drugs (i.e. CV more than 30 %).

My doubt is suppose the drug having the CV is 45%, then how can we decide whether we need to go 3 way or 4 way


Edit: Category changed; see also this post #1. [Helmut]

Complete thread:

UA Flag
Activity
 Admin contact
23,379 posts in 4,913 threads, 1,661 registered users;
240 visitors (0 registered, 240 guests [including 19 identified bots]).
Forum time: 20:42 CET (Europe/Vienna)

Science is what you know.
Philosophy is what you don’t know.    Bertrand Russell

The Bioequivalence and Bioavailability Forum is hosted by
BEBAC Ing. Helmut Schütz
HTML5